Trial Profile

Randomized Study of Efficacy & Safety of Lapatinib & Epirubicin & Cyclophosphamide (EC90) Followed by Paclitaxel & Lapatinib Compared With EC90 Followed by Paclitaxel & Trastuzumab, as Neoadjuvant Therapy in Patients With Previously Untreated ErbB2-overexpressing Stage I - IIIA Breast Cancer

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 31 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lapatinib (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel; Trastuzumab
Indications Advanced breast cancer; Early breast cancer
Focus Therapeutic Use
Acronyms ELATE
Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK

20 Dec 2021 This trial has been completed in Hungary (Global end date: 16 Dec 2010).
28 May 2019 This trial has been discontinued in Norway, according to European Clinical Trials Database.
02 May 2019 Trail was completed in France according to European Clinical Trials Database record. (global end date: 20 Jan 2011)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com